Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 2/2016

01-05-2016 | Review Article

Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors

Authors: Alexandra Papoudou-Bai, Alexandra Barbouti, Vassiliki Galani, Kalliopi Stefanaki, Dimitra Rontogianni, Panagiotis Kanavaros

Published in: Clinical and Experimental Medicine | Issue 2/2016

Login to get access

Abstract

The human thymus supports the production of self-tolerant T cells with competent and regulatory functions. Various cellular components of the thymic microenvironment such as thymic epithelial cells (TEC) and dendritic cells play essential roles in thymic T cell differentiation. The multiple cellular events occurring during thymic T cell and TEC differentiation involve proteins regulating cell cycle and apoptosis. Dysregulation of the cell cycle and apoptosis networks is involved in the pathogenesis of thymic epithelial tumors (TET) which are divided into two broad categories, thymomas and thymic carcinomas. The present review focuses on the usefulness of the analysis of the expression patterns of major cell cycle and apoptosis regulators in order to gain insight in the histophysiology of thymus and the histopathology, the clinical behavior and the biology of TET.
Literature
1.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.PubMedCrossRef
2.
Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–93.PubMedCrossRef
3.
Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell Signal. 2014;26:549–55.PubMedPubMedCentralCrossRef
4.
5.
6.
Stevens JB, Abdallah BY, Liu G, et al. Heterogeneity of cell death. Cytogenet Genome Res. 2013;139:164–73.PubMedCrossRef
7.
8.
Aichinger M, Wu C, Nedjic J, Klein L. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med. 2013;210:287–300.PubMedPubMedCentralCrossRef
9.
Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15:81–94.PubMedPubMedCentralCrossRef
10.
11.
12.
13.
Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.PubMedCrossRef
14.
15.
Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2012;19:107–20.PubMedPubMedCentralCrossRef
16.
Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013;1833:3448–59.PubMedCrossRef
17.
18.
Rezzani R, Bonomini F, Rodella LF. Histochemical and molecular overview of the thymus as site for T-cell development. Prog Histochem Cytochem. 2008;43:73–120.PubMedCrossRef
19.
20.
Papoudou-Bai A, Bai M, Doukas M, et al. Immunohistological characterization of thymic dendritic cells. In Vivo. 2012;26:985–92.PubMed
21.
Klein L, Hinterberger M, von Rohrscheidt J, Aichinger M. Autonomous versus dendritic cell-dependent contributions of medullary thymic epithelial cells to central tolerance. Trends Immunol. 2011;32:188–93.PubMedCrossRef
22.
Bronietzki AW, Schuster M, Schmitz I. Autophagy in T-cell development, activation and differentiation. Immunol Cell Biol. 2015;93:25–34.PubMedCrossRef
23.
Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev. 2013;22:75–87.PubMedCrossRef
24.
Serpico D, Trama A, Haspinger ER, et al. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Ann Oncol. 2014;. doi:10.​1093/​annonc/​mdu527.PubMed
25.
Weissferdt A, Wistuba I, Moran CA. Molecular aspects of thymic carcinoma. Lung Cancer. 2012;78:127–32.PubMedCrossRef
26.
Huang B, Belharazem D, Li L, et al. Anti-apoptotic signature in thymic squamous cell carcinomas—functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c. Fron Oncol. 2013;. doi:10.​3389/​fonc.​2013.​00316.
27.
Ströbel P, Hartmann E, Rosenwald A, et al. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology. 2014;64:557–66.PubMedCrossRef
28.
29.
Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria and reporting. J Thorac Oncol. 2014;9:596–611.PubMedCrossRef
30.
Stefanaki S, Rontogianni D, Kouvidou C, et al. Immunohistochemical expression of bcl2, p53, mdm2 and p21/waf-1 proteins in thymomas. Histopathology. 1997;30:549–55.PubMedCrossRef
31.
Kanavaros P, Stefanaki K, Rontogianni D, et al. Immunohistochemical expression of p53, p21/waf1, Rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus. Histol Histopathol. 2001;16:1005–12.PubMed
32.
Bai M, Doukas M, Papoudou-Bai A, et al. Immunohistological analysis of cell cycle and apoptosis regulators in thymus. Ann Anat. 2013;195:159–65.PubMedCrossRef
33.
Zisis C, Rontogianni D, Stefanaki K, Bellenis I. Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. Interact CardioVasc Thorac Surg. 2004;3:245–8.PubMedCrossRef
34.
Chen FF, Yan JJ, Chang KC, Lai WW, Chen RM, Jin YT. Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours. Histopathology. 1996;29:541–7.PubMedCrossRef
35.
Khoury T, Chandrasekhar R, Wilding G, Tan D, Cheney RT. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma. Int J Exp Pathol. 2011;92:87–96.PubMedPubMedCentralCrossRef
36.
Hayashi A, Fumon T, Miki Y, Sato H, Yoshino T, Takahashi K. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type B3 thymoma or lung squamous cell carcinoma. J Clin Exp Hematopathol. 2013;53:9–19.CrossRef
37.
Engel P, Francis D, Graem N. Expression of bcl-2 in fetal thymus, thymomas and thymic carcinomas. Association with p53 expression and review of the literature. APMIS. 1998;106:449–55.PubMedCrossRef
38.
Hirabayashi H, Fujii Y, Sakagushi M, et al. p16/INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer. 1997;73:639–44.PubMedCrossRef
39.
Ichimiya S, Kojima T, Momota H, et al. p73 is expressed in human thymic epithelial cells. J Histochem Cytochem. 2002;50:455–62.PubMedCrossRef
40.
Nagahama H, Hatakeyama S, Nakayama K, et al. Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p57Kip2 during mouse development. Anat Embryol. 2001;203:77–87.PubMedCrossRef
41.
Kitada S, Krajewska M, Zhang X, et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol. 1998;152:51–61.PubMedPubMedCentral
42.
Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res. 1994;56:2849–55.
43.
Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994;145:1323–36.PubMedPubMedCentral
44.
Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995;146:1309–19.PubMedPubMedCentral
45.
Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol. 2006;37:78–86.PubMedCrossRef
46.
Moulian N, Bidault J, Planche C, Berrih-Aknin S. Two signaling pathways can increase Fas expression in human thymocytes. Blood. 1998;92:1297–304.PubMed
47.
Moulian N, Renvoize C, Desodt C, Serraf A, Berrich-Aknin S. Functional Fas in human thymic epithelial cells. Blood. 1999;93:2660–70.PubMed
48.
Tateyama H, Eimoto T, Tada T, et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol. 1995;104:375–81.
49.
Chen FF, Yan JJ, Jin YT, Su IJ. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol. 1996;27:1089–92.PubMedCrossRef
50.
Pich A, Chiarle R, Chiusa L, Ponti R, Geuna M, Palestro G. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer. 1996;69:180–3.PubMedCrossRef
51.
Weirich G, Schneider P, Fellbaum C, et al. p53 alterations in thymic epithelial tumours. Virchows Arch. 1997;431:17–23.PubMedCrossRef
52.
Pan CC, Chen PCH, Wang LS, Lee JL, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology. 2003;43:165–72.PubMedCrossRef
53.
Park SH, Kim HK, Kim H, Ro JY. Apoptosis in thymic epithelial tumors. Pathol Res Pract. 2002;198:461–7.PubMedCrossRef
54.
Penault-Llorca F, Bouabdallah R, Devilard E, et al. Analysis of BAX expression in human tissues using the anti-BAX, 4F11 monoclonal antibody on paraffin sections. Pathol Res Pract. 1998;194:457–64.PubMedCrossRef
55.
Chilosi M, Iannucci A, Menestrina F, et al. Immunohistochemical evidence of active thymocyte proliferation in thymoma. Its possible role in the pathogenesis of autoimmune diseases. Am J Pathol. 1987;128:464–70.PubMedPubMedCentral
56.
Alexiev BA, Drachenberg CB, Burke AP. Thymomas: a cytological and immunohistochemical study, with emphasis on lymphoid and neuroendocrine markers. Diagn Pathol. 2007;12:1–10.
57.
Kojika M, Ishii G, Yoshida J, et al. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol. 2009;22:1341–50.PubMedCrossRef
58.
Spaulding B, Pan D, Ghadersohi A, et al. Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology. 2006;49:622–33.PubMedPubMedCentralCrossRef
59.
Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer. 1997;76:1361–6.PubMedPubMedCentralCrossRef
60.
Wu M, Sun K, Gil J, Gan L, Burstein DE. Immunohistochemical detection of p63 and XIAP in thymic hyperplasia and thymomas. Am J Clin Pathol. 2009;131:689–93.PubMedCrossRef
61.
Pan CC, Ho DM, Chen WY, Huang CW, Chiang H. Ki67 labelling index correlates with stage and histology but not significantly with prognosis in thymoma. Histopathology. 1998;33:453–8.PubMedCrossRef
62.
Baldi A, Ambrogi V, Mineo D, et al. Analysis of cell cycle regulator proteins in encapsulated thymomas. Clin Cancer Res. 2005;15:5078–83.CrossRef
63.
Dotto J, Pelosi G, Rosai J. Expression of p63 in thymomas and normal thymus. Am J Clin Pathol. 2007;127:415–20.PubMedCrossRef
64.
Hiroshima K, Iyoda A, Toyozaki T, et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol. 2002;15:1326–32.PubMedCrossRef
65.
Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012;19(3):e351.CrossRef
66.
Khoury T, Arshad A, Bogner P, et al. Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest. 2009;136:220–8.PubMedCrossRef
67.
Yang WI, Efird JT, Quintanilla-Martinez L, Choi N, Harris NL. Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol. 1996;27:70–6.PubMedCrossRef
68.
Ma Y, Li Q, Cui W, et al. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Diagn Pathol. 2010;14:120–7.
69.
Mineo TC, Ambrogi V, Mineo D, Baldi A. Long-term disease free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression. Cancer. 2005;104:2063–71.PubMedCrossRef
70.
Mineo TC, Ambrogi V, Baldi A, Pompeo E, Mineo D. Recurrent intrathoracic thymomas: potential prognostic importance of cell-cycle protein expression. J Thorac Cardiovasc Surg. 2009;138:40–5.PubMedCrossRef
71.
Tateyama H, Eimoto T, Tada T, Inagaki H, Hattori H, Takino H. Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors. Mod Pathol. 1997;10:983–91.PubMed
72.
Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN. Immunohistochemical survey of p16/1NK4A expression in normal human adult and infant tissues. Lab Invest. 1999;79:1137–43.PubMed
73.
Chilosi M, Doglioni C, Yan Z, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol. 1998;152:209–17.PubMedPubMedCentral
74.
Shiraishi J, Utsuyama M, Seki S, et al. Essential microenvironment for thymopoiesis is preserved in human adult and aged thymus. Clin Dev Immunol. 2003;10:53–9.PubMedPubMedCentralCrossRef
75.
Gui J, Zhu X, Dohkan J, Cheng L, Barnes PF, Su DM. The aged thymus shows normal recruitment of lymphohematopoietic progenitors but has defects in thymic epithelial cells. Int Immunol. 2007;19:1201–11.PubMedCrossRef
76.
Shakib S, Desanti GE, Jenkinson DW, Parnell SM, Jenkinson EJ, Anderson G. Checkpoints in the development of thymic cortical epithelial cells. J Immunol. 2009;182:130–7.PubMedCrossRef
77.
Rodriguez-Puebla ML, LaCava M, Miliani De Marval PL, Jorcano JL, Richie ER, Conti CJ. Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol. 2000;157:1039–50.
78.
Robles AI, Larcher F, Whalin RB, et al. Expression of cyclin Dl in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci USA. 1996;93:7634–8.PubMedPubMedCentralCrossRef
79.
Scheijen B, Bronk M, van der Meer T, De Jong D, Bernards R. High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem. 2004;279:10476–83.PubMedCrossRef
80.
Williams O, Gil-Gomez G, Norton T, Kioussis D, Brady HJM. Activation of Cdk2 is a requirement for antigen-mediated thymic negative selection. Eur J Immunol. 2000;30:709–13.PubMedCrossRef
81.
Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27 (Kip1). J Clin Invest. 1999;103:597–604.PubMedPubMedCentralCrossRef
82.
Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cell. Oncogene. 1997;14:929–35.PubMedCrossRef
83.
Uhrbom L, Nister M, Wastermark B. Induction of senescence in human malignant glioma cells by p16/INK4A. Oncogene. 1997;15:505–14.PubMedCrossRef
84.
Krisnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114:1299–307.CrossRef
85.
Aw D, Silva AB, Maddick M, von Zglinicki T, Palmer DB. Architectural changes in the thymus of aging mice. Aging Cell. 2007;7:158–67.CrossRef
86.
French LE, Wilson A, Hanhe M, Viard I, Tschopp J, McDonald HR. Fas ligand expression is restricted to nonlymphoid thymic components in situ. J Immunol. 1997;159:2196–202.PubMed
87.
Yajima N, Sakamaki K, Yonehara S. Age-related thymic involution is mediated by Fas on thymic epithelial cells. Int Immunol. 2004;16:1027–35.PubMedCrossRef
88.
89.
Ogasawara J, Suda T, Nagata S. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med. 1995;181:485–91.PubMedCrossRef
90.
Jenkins M, Keir M, McCune JM. Fas is expressed early in human thymocyte development but does not transmit an apoptotic signal. J Immunol. 1999;163:1195–204.PubMed
91.
Resendez AR, Majo N, Segales J, et al. Apoptosis in normal lymphoid organs from healthy normal, conventional pigs at different ages detected by TUNEL and cleaved caspase-3 immunohistochemistry in paraffin-embedded tissues. Vet Immunol Immunopathol. 2004;99:203–13.CrossRef
92.
93.
Kataoka T, Ito M, Budd RC, Tschopp J, Nagai K. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells. Exp Cell Res. 2002;273:256–64.PubMedCrossRef
94.
Kobayashi Y, Yukiue H, Sasaki H, et al. Developmentally regulated expression of survivin in the human thymus. Hum Immunol. 2002;63:101–7.PubMedCrossRef
95.
96.
Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol. 2002;3:932–9.PubMedCrossRef
97.
Dunkle A, Dzhagalov I, He YW. Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2. Cell Death Differ. 2010;17:994–1002.PubMedPubMedCentralCrossRef
98.
Dzhagalov I, Dunkle A, He YW. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J Immunol. 2008;181:521–8.PubMedPubMedCentralCrossRef
99.
Grillot DA, Merino R, Núñez G. Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med. 1995;182:1973–83.PubMedCrossRef
100.
Yang CY, Lin NH, Lee JM, et al. Promoter knock-in mutations reveal a role of mcl-1 in thymocyte-positive selection and tissue or cell lineage specific regulation of mcl-1 expression. J Immunol. 2009;182:2959–68.PubMedCrossRef
101.
Yokoyama T, Tanahashi M, Kobayashi Y, et al. The expression of Bcl-2 family proteins (Bcl-2, Bcl-x, Bax, Bak and Bim) in human lymphocytes. Immunol Lett. 2002;81:107–13.PubMedCrossRef
102.
Hutcheson J, Scatizzi JC, Bickel E, et al. Combined loss of proapoptotic genes Bak or Bax with Bim synergizes to cause defects in hematopoiesis and in thymocyte apoptosis. J Exp Med. 2005;201:1949–60.PubMedPubMedCentralCrossRef
103.
Candi E, Rufini A, Terrinoni A, et al. p63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc Natl Acad Sci USA. 2007;104:11999–2004.PubMedPubMedCentralCrossRef
104.
Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007;129:523–36.PubMedCrossRef
105.
Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development. 2006;133:1553–63.PubMedCrossRef
106.
Revest JM, Suniara RK, Kerr K, Owen JJ, Dickson C. Development of the thymus requires signaling through the fibroblast growth factor receptor R2-IIIb. J Immunol. 2001;167:1954–61.PubMedCrossRef
107.
Dooley J, Erickson M, Larochelle WJ, Gillard GO, Farr AG. FGFR2IIIb signaling regulates thymic epithelial differentiation. Dev Dyn. 2007;236:3459–71.PubMedCrossRef
108.
Sarafian V, Marinova TT. Lysosomal membrane-associated glycoproteins are differentially expressed in acute and chronic human thymic involution. Acta Biol Hung. 2006;57:315–22.PubMedCrossRef
109.
Sarafian V, Marinova TT, Gulubova MV. Differential expression of LAMPs and ubiquitin in human thymus. APMIS. 2009;117:248–52.PubMedCrossRef
110.
111.
112.
Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012;137:444–50.PubMedCrossRef
113.
Moran CA, Walsh G, Suster S, Kaiser L. Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol. 2012;137:451–61.PubMedCrossRef
114.
Su XY, Wu WL, Liu N, Zhang SF, Li GD. Thymic epithelial tumors: a clinicopathologic study of 249 cases from a single institution. Int J Clin Exp Pathol. 2014;7:7760–7.PubMedPubMedCentral
115.
Baik S, Jenkinson EJ, Lane PJ, Anderson G, Jenkinson WE. Generation of both cortical and Aire(+) medullary thymic epithelial compartments from CD205(+) progenitors. Eur J Immunol. 2013;43:589–94.PubMedPubMedCentralCrossRef
116.
Peterson P, Laan M. Bipotency of thymic epithelial progenitors comes in sequence. Eur J Immunol. 2013;43:580–3.PubMedCrossRef
117.
Alexandropoulos K, Bonito AJ, Weinstein EG, Herbin O. Medullary thymic epithelial cells and central tolerance in autoimmune hepatitis development: novel perspective from a new mouse model. Int J Mol Sci. 2015;16:1980–2000.PubMedPubMedCentralCrossRef
118.
Alves NL, Takahama Y, Ohigashi I, et al. Serial progression of cortical and medullary thymic epithelial microenvironments. Eur J Immunol. 2014;44:16–22.PubMedPubMedCentralCrossRef
119.
Nitta T, Ohigashi I, Nakagawa Y, Takahama Y. Cytokine crosstalk for thymic medulla formation. Curr Opin Immunol. 2011;23:190–7.PubMedCrossRef
120.
Anderson G, Takahama Y. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol. 2012;33:256–63.PubMedCrossRef
121.
Ströbel P, Helmreich M, Menioudakis G, et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood. 2002;100:159–66.PubMedCrossRef
122.
Okumura M, Fujii Y, Shiono H, et al. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg. 2008;56:143–50.PubMedCrossRef
Metadata
Title
Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors
Authors
Alexandra Papoudou-Bai
Alexandra Barbouti
Vassiliki Galani
Kalliopi Stefanaki
Dimitra Rontogianni
Panagiotis Kanavaros
Publication date
01-05-2016
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2016
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0344-7

Other articles of this Issue 2/2016

Clinical and Experimental Medicine 2/2016 Go to the issue

Short Communication

CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus

Letter to the Editor

Comment on: “Autoimmune uveitis: clinical, pathogenetic, and therapeutic features”

Review Article

The synovio-entheseal complex in enthesoarthritis

Original Article

Significance of decreased serum interleukin-10 levels in the progression of cerebral infarction

Original Article

The effects of SP110’s associated genes on fresh cavitary pulmonary tuberculosis in Han Chinese population

Original Article

Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits